In Depth 15 Oct 2025 The advent of AI for peptide design: An emerging field Discover the emerging field of AI-based peptide discovery and design – could this signal the beginning of a golden age for peptides? October 15, 2025 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2025 First-ever approval for Barth Syndrome treatment: what does this mean for ultra-rare disease therapeutics? FDA approval for Stealth BioTherapeutics’ elamipretide has been a long time coming. What does this mean for other ultra-rare disease companies? September 29, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2025 GLP-1 drugs on WHO Essential Medicines List: what’s the impact? The WHO has added GLP-1 agonists to its Essential Medicines List in 2025. Learn more about the impact of this decision. September 19, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Sponsored by Lonza 9 Sep 2025 Advanced expression vector design to overcome challenges in developing multichain biotherapeutics Learn how multichain biotherapeutics like bispecific antibodies and Fc-fusion proteins overcome manufacturing challenges with advanced vectors and expression systems. September 9, 2025 - 8 minutesmins - By Jennifer Tsang Share WhatsApp Twitter Linkedin Email
In Depth 16 Jun 2025 Did Novo open the Canadian market to GLP-1 generics? Find out if Novo’s GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a small fee? June 16, 2025 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 28 May 2025 New weight loss drugs: Biotech’s mission to end obesity Find out more about biotech’s mission to end obesity, as we look at the new weight loss drugs that are in development. May 28, 2025 - 17 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 7 May 2025 Top biotech deals of April 2025 Learn about April 2025’s top biotech deals, featuring major collaborations in bispecific antibodies, protein therapies, and drug delivery. May 7, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 14 Mar 2025 Can GLP-1 agonists help treat addiction? Discover how researchers have been exploring the potential of GLP-1 drugs for treating addiction disorders. March 14, 2025 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 2 Dec 2024 The rise of cancer vaccines: A new era in immunotherapy Delve into the expanding and diverse field of cancer vaccines with various approaches exploiting the immune system to fight tumors. December 2, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 14 Oct 2024 Six biomimicry biotech companies harnessing nature’s wisdom to develop breakthrough drug candidates Find out more about six biomimicry companies harnessing nature’s wisdom to create drug candidates for the benefit of human health. October 14, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 7 Oct 2024 Spinal cord injury: Are we getting closer to a treatment? Delve into the spinal cord injury treatment landscape with a few pharmaceutical approaches that could tackle this complex condition. October 7, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Sponsored by Sublin Therapeutics 1 Oct 2024 Sublingual delivery: the future for GLP-1 receptor agonists Discover how GLP-1 receptor agonists, now thriving in obesity treatment, could benefit from a more patient-friendly sublingual delivery method. October 1, 2024 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email